WINTON GROUP Ltd Purchases Shares of 65,345 Collegium Pharmaceutical, Inc. $COLL

WINTON GROUP Ltd purchased a new stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 65,345 shares of the specialty pharmaceutical company’s stock, valued at approximately $2,286,000. WINTON GROUP Ltd owned about 0.21% of Collegium Pharmaceutical as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Federated Hermes Inc. increased its holdings in Collegium Pharmaceutical by 67.0% in the third quarter. Federated Hermes Inc. now owns 872 shares of the specialty pharmaceutical company’s stock valued at $31,000 after purchasing an additional 350 shares during the period. Hantz Financial Services Inc. raised its position in Collegium Pharmaceutical by 137.7% during the 3rd quarter. Hantz Financial Services Inc. now owns 1,714 shares of the specialty pharmaceutical company’s stock worth $60,000 after purchasing an additional 993 shares during the last quarter. EverSource Wealth Advisors LLC lifted its holdings in Collegium Pharmaceutical by 744.9% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,484 shares of the specialty pharmaceutical company’s stock worth $73,000 after buying an additional 2,190 shares during the period. NewEdge Advisors LLC lifted its holdings in Collegium Pharmaceutical by 304.6% during the 2nd quarter. NewEdge Advisors LLC now owns 3,047 shares of the specialty pharmaceutical company’s stock worth $90,000 after buying an additional 2,294 shares during the period. Finally, EMC Capital Management bought a new stake in shares of Collegium Pharmaceutical in the 2nd quarter valued at about $97,000.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on COLL. Truist Financial set a $58.00 price target on Collegium Pharmaceutical in a research note on Tuesday, February 10th. Wall Street Zen cut Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 28th. Barclays decreased their target price on shares of Collegium Pharmaceutical from $58.00 to $56.00 and set an “overweight” rating for the company in a research report on Friday, January 9th. Zacks Research downgraded shares of Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 6th. Finally, Weiss Ratings lowered shares of Collegium Pharmaceutical from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Thursday, March 5th. Four research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $53.00.

Insider Activity at Collegium Pharmaceutical

In other news, EVP Scott Dreyer sold 49,976 shares of Collegium Pharmaceutical stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $40.41, for a total value of $2,019,530.16. Following the completion of the sale, the executive vice president owned 71,770 shares in the company, valued at $2,900,225.70. The trade was a 41.05% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 2.51% of the stock is currently owned by company insiders.

Collegium Pharmaceutical Stock Down 1.8%

Shares of Collegium Pharmaceutical stock opened at $36.61 on Wednesday. Collegium Pharmaceutical, Inc. has a one year low of $23.23 and a one year high of $50.79. The company has a debt-to-equity ratio of 2.59, a current ratio of 1.57 and a quick ratio of 1.48. The stock’s 50-day moving average is $45.03 and its 200 day moving average is $42.11. The firm has a market cap of $1.16 billion, a price-to-earnings ratio of 21.41 and a beta of 0.67.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its earnings results on Thursday, February 26th. The specialty pharmaceutical company reported $2.04 earnings per share for the quarter, missing analysts’ consensus estimates of $2.20 by ($0.16). Collegium Pharmaceutical had a return on equity of 98.65% and a net margin of 8.05%.The business had revenue of $205.45 million during the quarter, compared to the consensus estimate of $206.36 million. During the same quarter in the previous year, the firm posted $1.77 earnings per share. The company’s revenue for the quarter was up 12.9% compared to the same quarter last year. Equities research analysts anticipate that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current year.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.